AbbVie may count on Allergan's Botox for post-merger growth. But what else?

Botox Treatment
After a growth quarter for Allergan's Botox, AbbVie is looking at the drug as a post-merger business driver. (Getty Images)

With a $63 billion merger nearing approval, AbbVie is counting on Allergan and its cash-cow Botox to boost sales—and that superstar could be a long-term winner. But not every drug in Allergan's stable is shining quite so brightly. 

Cosmetic and therapeutic Botox combined for $927.8 million in global sales in the third quarter, a 5.8% increase over the previous year, Allergan said Tuesday. Cosmetic sales in the U.S. grew the most, delivering $237.6 million––a 10% increase from the previous year. 

Botox's success has been a point of pride for AbbVie as it seeks to close its merger with Allergan in early 2020 and add some fresh air to the new company's offerings. 

RELATED: Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say

Suggested Articles

Besides paying $729 million to settle notorious kickback allegations, Novartis has promised to put strict restrictions on its future speaker programs.

Pharma companies including Pfizer and Novartis paused advertising on Facebook for July to protest hate and disinformation on the platform.

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.